FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Margaret Dugan

Research Profile

Chemicals & Drugs

Concepts & Ideas

Disorders

Procedures

Administration, Oral

Co-author Network

Publications

TOP 3
José Baselga; Clifford DiLea; Margaret Dugan; Herlinde Dumez; Jerry Huang; Christie Low; Erika Martinelli; William Mietlowski; Alain C Mita; Kathryn Parker; Frederico Rojo; Patrick Schöffski; Josep Tabernero; Allan van Oosterom; Eric Walk; Chris H Takimoto
Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.
David A Reardon; Jane Xia; Kenneth D Aldape; Wei Chen; Timothy Cloughesy; Charles A Conrad; Clifford DiLea; Margaret Dugan; Henry S Friedman; Jerry Huang; William Mietlowski; Paul Mischel; Michael D Prados; W K Alfred Yung
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
Francis Giles; Thomas Fischer; Jorge Cortes; Guillermo Garcia-Manero; Joachim Beck; Farhad Ravandi; Eric Masson; Patricia Rae; Glen Laird; Sunil Sharma; Andrew Lamb; Margaret Dugan; Maher Albitar; Kapil N Bhalla
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Margaret Dugan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: José Baselga; Clifford DiLea; Margaret Dugan; Herlinde Dumez; Jerry Huang; Christie Low; Erika Martinelli; William Mietlowski; Alain C Mita; Kathryn Parker; Frederico Rojo; Patrick Schöffski; Josep Tabernero; Allan van Oosterom; Eric Walk; Chris H Takimoto
Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(22):6364-72.
2012: David A Reardon; Jane Xia; Kenneth D Aldape; Wei Chen; Timothy Cloughesy; Charles A Conrad; Clifford DiLea; Margaret Dugan; Henry S Friedman; Jerry Huang; William Mietlowski; Paul Mischel; Michael D Prados; W K Alfred Yung
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
Cancer chemotherapy and pharmacology 2012;69(6):1507-18.
2006: Francis Giles; Thomas Fischer; Jorge Cortes; Guillermo Garcia-Manero; Joachim Beck; Farhad Ravandi; Eric Masson; Patricia Rae; Glen Laird; Sunil Sharma; Andrew Lamb; Margaret Dugan; Maher Albitar; Kapil N Bhalla
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4628-35.
2006: Andrew Lamb; Francis Giles; Lydia Wunderle; Kapil N Bhalla; Susan O'Brien; Barbara Wassmann; Chiaki Tanaka; Paul Manley; Patricia Rae; William Mietlowski; Kathy Bochinski; Andreas Hochhaus; James D Griffin; Dieter Hoelzer; Maher Albitar; Margaret Dugan; Jorge Cortes; Leila Alland; Oliver G Ottmann
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
The New England journal of medicine 2006;354(24):2542-51.
2005: Srdan Verstovsek; Mirna Golemovic; Andrew Lamb; Taghi Manshouri; Zeev Estrov; Paul Manley; Tong Sun; Ralph B Arlinghaus; Leila Alland; Margaret Dugan; Jorge Cortes; Francis Giles; Miloslav Beran
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
Cancer 2005;104(6):1230-6.
2005: Mirna Golemovic; Srdan Verstovsek; Francis Giles; Jorge Cortes; Taghi Manshouri; Paul W Manley; Jürgen Mestan; Margaret Dugan; Leila Alland; James D Griffin; Ralph B Arlinghaus; Tong Sun; Andrew Lamb; Miloslav Beran
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4941-7.
2005: Joachim Drevs; Ute Zirrgiebel; Carmen Schmidt-Gersbach; Klaus Mross; Michael Medinger; Lucy Lee; J Pinheiro; Jeanette Wood; Anne L Thomas; Clemens Unger; Andrew Henry; William P Steward; Dirk Laurent; David Lebwohl; Margaret Dugan; Dieter Marmé
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(4):558-65.
2003: Bruno Morgan; Anne L Thomas; Joachim Drevs; Jürgen Hennig; Martin Buchert; Asvina Jivan; Mark A Horsfield; Klaus Mross; Howard A Ball; Lucy Lee; William Mietlowski; Stefan Fuxuis; Clemens Unger; Ken O'Byrne; Andrew Henry; Graham R Cherryman; Dirk Laurent; Margaret Dugan; Dieter Marmé; William P Steward
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(21):3955-64.
2003: Anne L Thomas; Bruno Morgan; Joachim Drevs; Clemens Unger; Bertram Wiedenmann; Udo Vanhoefer; Dirk Laurent; Margaret Dugan; William P Steward
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.
Seminars in oncology 2003;30(3 Suppl 6):32-8.
2002: Linda S Lashford; P Thiesse; A Jouvet; Timothy Jaspan; Dominique Couanet; P D Griffiths; F Doz; James Ironside; K Robson; Rachel Hobson; Margaret Dugan; Andrew D J Pearson; Gilles Vassal; Didier Frappaz
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(24):4684-91.
2001: M Brada; K Hoang-Xuan; Roy Rampling; P Y Dietrich; L Y Dirix; D Macdonald; Jan J Heimans; BA Zonnenberg; J M Bravo-Marques; R Henriksson; R Stupp; N Yue; Janet Bruner; Margaret Dugan; S Rao; Sara Zaknoen
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(2):259-66.
1999: M Brada; I Judson; P Beale; S Moore; P Reidenberg; Paul Statkevich; Margaret Dugan; Vijay K Batra; David Cutler
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
British journal of cancer 1999;81(6):1022-30.
1999: W K Alfred Yung; Michael D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; Henry S Friedman; Robert Albright; John Olson; Susan M Chang; A M O'Neill; Allan H Friedman; Janet Bruner; N Yue; Margaret Dugan; Sara Zaknoen; Victor Levin
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
1999: Lisa A Hammond; John R Eckardt; Sharyn D Baker; S Gail Eckhardt; Margaret Dugan; K Forral; P Reidenberg; Paul Statkevich; Geoffrey R Weiss; David A Rinaldi; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2604-13.
1999: Sharyn D Baker; M Wirth; Paul Statkevich; P Reidenberg; Kevin B Alton; SE Sartorius; Margaret Dugan; David Cutler; Vijay K Batra; Louise B. Grochow; Ross C Donehower; Eric K Rowinsky
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):309-17.
1998: EJ Estlin; Linda S Lashford; S Ablett; L Price; R Gowing; A Gholkar; J Kohler; Ian J Lewis; Bruce Morland; C Ross Pinkerton; M C Stevens; M Mott; R Stevens; David R Newell; D Walker; C Dicks-Mireaux; Heather McDowell; P Reidenberg; Paul Statkevich; A Marco; Vijay K Batra; Margaret Dugan; Andrew D J Pearson
Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.
British journal of cancer 1998;78(5):652-61.